Fisher Asset Management
RARE icon

Fisher Asset Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Fisher Asset Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-198,696
Closed -$4.57M – 1094
2025
Q4 		$4.57M Buy
198,696
+30,612
+18% +$1.01M ﹤0.01% 476
2025
Q3 		$5.06M Sell
168,084
-17,672
-10% -$530K ﹤0.01% 479
2025
Q2 		$6.75M Sell
185,756
-21,999
-11% -$793K ﹤0.01% 444
2025
Q1 		$7.52M Sell
207,755
-57,434
-22% -$2.39M ﹤0.01% 449
2024
Q4 		$11.2M Buy
+265,189
New +$13.2M ﹤0.01% 418

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Fisher Asset Management's RARE Position: Q1 2026 in Review

Fisher Asset Management sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2026, closing a stake of 198,696 shares — an estimated $4.57M sold.

Fisher Asset Management first reported a position in RARE in Q4 2024 and held it in 5 quarters. The position peaked at $11.2M in Q4 2024. 298 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Fisher Asset Management reported no remaining Ultragenyx Pharmaceutical position as of Q1 2026 after selling out during the quarter.
  • Fisher Asset Management sold 198,696 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $4.57M.
  • Fisher Asset Management first reported a position in Ultragenyx Pharmaceutical in Q4 2024 and held it in 5 quarters.
  • Fisher Asset Management's Ultragenyx Pharmaceutical position peaked at $11.2M in Q4 2024.
  • 298 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Fisher Asset Management's 13F filing for Q1 2026, filed 5 May 2026.